Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quidel, Digene Among Diagnostic Stocks To Rebound, Excel In 2003

This article was originally published in The Gray Sheet

Executive Summary

Increased national disease awareness benefited in vitro diagnostics developers in 2003 as new U.S. testing guidelines and the SARS pandemic combined with recovery in the broader economic market to help fuel growth
Advertisement

Related Content

Datascope Stock Rebounds With ProLumen Introduction; OTC Index Up 3%
Datascope Stock Rebounds With ProLumen Introduction; OTC Index Up 3%
Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003
Roche Amplicor HPV Test To Battle With Digene: A David & Goliath Scenario?
Roche Amplicor HPV Test To Battle With Digene: A David & Goliath Scenario?
Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004
Advertisement
UsernamePublicRestriction

Register

MT019594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel